Phase II Treatment of Adults With Brain Metastases With Temodar
OBJECTIVES:
- Determine the activity of temozolomide in patients with brain metastases.
- Determine the toxicity of this treatment in these patients.
OUTLINE: Patients are stratified according to type of primary cancer (lung carcinoma vs
breast carcinoma vs malignant melanoma vs renal cell carcinoma vs colorectal carcinoma vs
other).
Patients receive oral temozolomide daily on days 1-7 and 15-21. Treatment repeats every 28
days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 180 patients (30 per stratum) will be accrued for this study.
Interventional
Primary Purpose: Treatment
Henry S. Friedman, MD
Study Chair
Duke University
United States: Federal Government
2114
NCT00005954
August 2000
June 2003
Name | Location |
---|---|
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |